Area of research
Hematology · Genetics
Research interest
Research focused on Bosutinib and Imatinib, with related work in Chronic myeloid leukaemia, Stem cell, Cancer research. Notable publications include 'Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the...', 'European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia', and 'PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells'.
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells